Pre-emptive skin treatments to prevent skin toxicity caused by anti-EGFR antibody: the real-world evidence in Japan

被引：2

作者：

Yamazaki, Naoya ^{[1
]}

Oomuku, Yumi ^{[2
]}

Mishiro, Izumi ^{[3
]}

Soeda, Junpei ^{[2
]}

机构：

[1] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[2] Takeda Pharmaceut Co Ltd, Japan Med Affairs, Japan Oncol Business Unit, Tokyo, Japan

[3] Takeda Pharmaceut Co Ltd, Japan Med Affairs, Japan Pharma Business Unit, Tokyo, Japan

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 30期

关键词：

cetuximab; colorectal cancer; dermatologist visit; EGFR; Japanese; panitumumab; pre-emptive; real-world data; skin toxicity; METASTATIC COLORECTAL-CANCER; CONTROLLED-TRIAL; PANITUMUMAB; RASH; MINOCYCLINE; CETUXIMAB; BREAST;

D O I：

10.2217/fon-2018-0379

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Clinically managing skin toxicity associated with anti-EGFR antibody usage to treat colorectal cancer improves quality of life for colorectal cancer patients. This study assesses trends of pre-emptive skin treatments and their impact on subsequent dermatologist visits in Japanese colorectal cancer patients. Patients & methods: Pre-emptive treatment status and dermatologist visit data were investigated for 9461 colorectal cancer patients who experienced anti-EGFR antibody treatment. Data were collected from an electronic hospital-based claims database. Results: Pre-emptive treatments increased around 2013. Furthermore, subsequent dermatologist visits decreased significantly among the pre-emptive treatment group (p<0.05). Conclusion: Pre-emptive skin treatments seem to be related to reducing subsequent dermatologist visits by severe skin toxicity prevention and gained popularity in Japan.

引用

页码：3163 / 3174

页数：12

共 25 条

[1] Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study [J].